Literature DB >> 34110033

Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort.

Christoph Würnschimmel1,2, Mykyta Kachanov1, Mike Wenzel2,3, Philipp Mandel3, Pierre I Karakiewicz2, Tobias Maurer1,4, Thomas Steuber1,4, Derya Tilki1,4, Markus Graefen4, Lars Budäus1.   

Abstract

BACKGROUND: A trend towards inverse stage migration in prostate cancer (PCa) was reported. However, previous analyses did not take into account potential differences in sampling strategies (number of biopsy cores), which might have confounded these reports.
MATERIAL AND METHODS: Within our single-institutional database we identified PCa patients treated with radical prostatectomy (RP) between 2000 and 2020 (n = 21,646). We calculated the estimated annual percentage change (EAPC) for D'Amico risk groups, biopsy Gleason Grade Group (GGG), PSA and cT stage as well as postoperative RP GGG and pT stage relying on log linear regression methodology. Subsequently, we repeated the analyses after adjustment for number of cores obtained at biopsy.
RESULTS: Absolute rates of D'Amico low risk decreased (-30.1%), while intermediate and high risk increased (+21.2% and +9.0%, respectively). Rates of GGG I decreased (-50.0%), while GGG II-V increased, with the largest increase in GGG II (+22.5%). This trend, albeit less pronounced, was also recorded after adjusted EAPC analyses (p < .05). Specifically, EAPC values for D'Amico low vs intermediate vs high risk were -1.07%, +0.37%, +0.45%, respectively, and EAPC values for GGG ranged between -0.71% (GGG I) and +0.80% (GGG IV). Finally, an increase in ≥cT2 (EAPC: +3.16%) was displayed (all p < .001). These trends were confirmed in EAPC calculations in RP GGG and pT stages (p < .001).
CONCLUSION: Our findings confirm the trend towards less frequent treatment of low risk PCa and more frequent treatment of high risk PCa, also after adjustment for number of biopsy cores.
© 2021 The Authors. The Prostate Published by Wiley Periodicals LLC.

Entities:  

Keywords:  Gleason Grade Group; biopsy cores; clinical stage; risk group; stage migration

Mesh:

Year:  2021        PMID: 34110033     DOI: 10.1002/pros.24181

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  2 in total

1.  Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients.

Authors:  Rocco S Flammia; Benedikt Hoeh; Lukas Hohenhorst; Gabriele Sorce; Francesco Chierigo; Andrea Panunzio; Zhe Tian; Fred Saad; Costantino Leonardo; Alberto Briganti; Alessandro Antonelli; Carlo Terrone; Shahrokh F Shariat; Umberto Anceschi; Markus Graefen; Felix K H Chun; Francesco Montorsi; Michele Gallucci; Pierre I Karakiewicz
Journal:  Int Urol Nephrol       Date:  2022-07-15       Impact factor: 2.266

2.  Diagnosis of Clinically Significant Prostate Cancer Diagnosis Without Histological Proof in the Prostate-specific Membrane Antigen Era: The Jury Is Still Out.

Authors:  Mike Wenzel; Benedikt Hoeh; Philipp Mandel; Felix Kh Chun
Journal:  Eur Urol Open Sci       Date:  2022-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.